| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Chief Scientific Officer | Employee Stock Option (right to buy) | 230,000 | 04 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 04 Feb 2026 | 1 | $0 | 4 | Chief Scientific Officer | 05 Feb 2026, 16:12 |
| PRLD | Prelude Therapeutics Inc | 04 Feb 2025 | 1 | $0 | 4 | Chief Scientific Officer | 05 Feb 2025, 16:32 |
| PRLD | Prelude Therapeutics Inc | 01 Mar 2024 | 1 | $0 | 4 | Chief Scientific Officer | 04 Mar 2024, 18:07 |
| PRLD | Prelude Therapeutics Inc | 07 Feb 2023 | 1 | $0 | 4 | Chief Scientific Officer | 09 Feb 2023, 15:08 |
| PRLD | Prelude Therapeutics Inc | 15 Feb 2022 | 1 | $0 | 4 | Chief Scientific Officer | 17 Feb 2022, 18:12 |
| PRLD | Prelude Therapeutics Inc | 26 Aug 2021 | 8 | -$264,756 | 4 | Chief Scientific Officer | 30 Aug 2021, 17:16 |
| PRLD | Prelude Therapeutics Inc | 13 Aug 2021 | 5 | -$76,636 | 4 | Chief Scientific Officer | 17 Aug 2021, 16:44 |
| PRLD | Prelude Therapeutics Inc | 27 Jul 2021 | 4 | -$680,780 | 4 | Chief Scientific Officer | 29 Jul 2021, 19:27 |
| PRLD | Prelude Therapeutics Inc | 20 Jul 2021 | 1 | $0 | 4 | Chief Scientific Officer | 22 Jul 2021, 18:17 |
| PRLD | Prelude Therapeutics Inc | 07 May 2021 | 5 | -$393,892 | 4 | Chief Scientific Officer | 11 May 2021, 18:46 |